Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Reference82 articles.
1. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women;Gradishar;Oncology,2005
2. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group;Group-EBCTC;Lancet,1998
3. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer;Fennessy;Br J Surg,2004
4. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only;Horobin;Br J Surg,1991
5. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment;Howell;J Clin Oncol,2002
Cited by 107 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. GREB1L overexpression is associated with good clinical outcomes in breast cancer;European Journal of Medical Research;2023-11-14
2. Resistance to hormone therapy in breast cancer cells promotes autophagy and EGFR signaling pathway;American Journal of Physiology-Cell Physiology;2023-09-01
3. Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment;Journal of Experimental & Clinical Cancer Research;2023-08-18
4. Inhibition of Autophagy and the Cytoprotective Role of Smac Mimetic against ROS-Induced Cancer: A Potential Therapeutic Strategy in Relapse and Chemoresistance Cases in Breast Cancer;Current Issues in Molecular Biology;2023-07-10
5. Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment;2023-04-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3